LAUSR

To examine the relationship between lean body mass (LBM) and the incidence and severity of neutropenia in patients with malignant tumors from Northern China who have received nanoparticle albumin-bound paclitaxel. Twenty-six patients with pathologically confirmed malignant tumors were prospectively included in this study. These 26 patients were divided into group A (sarcopenia) and group B (non-sarcopenia). Group A comprised 50% (13/26) of the 26 patients, while group B comprised the other 50% (13/26). There was no statistically significant difference between both groups in terms of body surface area (BSA) (P = 0.052). The incidence of neutropenia in group A was 76.9% compared to 61.5% in group B (P = 0.0673). The incidence of grade 3 and severe neutropenia was 76.9% versus 61.5% in groups A and B, respectively (P = 0.645). These 26 patients were divided into groups 1 and 2 based on the administered nab-paclitaxel dose per kilogram of LBM, with both groups receiving a BSA dose of 260 mg/m2 . Group 1 received a nab-paclitaxel dose of 14.19 mg/kg of LBM, while group 2 received 11.37 mg/ kg of LBM. In group 1, the incidence of neutropenia was 71.4% whereas it was 66.7% in group 2. Grade 3 or higher neutropenia incidence was 28.6% in group 1 versus 16.7% in group 2. Patients with sarcopenia in Northern China experienced a higher incidence of severe neutropenia after receiving nab-paclitaxel than non-sarcopenia patients. Higher drug dose intensity per unit LBM may be a contributing factor. This article is protected by copyright. All rights reserved.